Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
Front Nutr ; 10: 1221935, 2023.
Article in English | MEDLINE | ID: mdl-37876615

ABSTRACT

Tetrahydrocurcumin (THC) has been shown to possess anti-angiogenic activities. This study aims to investigate the effects of THC on adipose angiogenesis and expression of angiogenic factors that occurs in 60% high-fat diet-induced obese mice. Male ICR mice were randomly divided into 3 groups: mice fed with a low-fat diet (LFD group); mice fed with very high fat diet (VHFD group), and mice fed with VHFD supplemented with THC (300 mg/kg/day orally) (VHFD+THC treated group) for 6 weeks. Body weight (BW), food intake, fasting blood sugar (FBS), lipid profiles and visceral fats weight (VF) were measured. The microvascular density (MVD), TNF-α, VEGF, MMP-2, and MMP-9 expressions were evaluated. The VHFD group had significantly increased total cholesterol, triglyceride, food intake, BW, VF, VF/BW ratio, adipocyte size and the number of crown-liked structures as compared to LFD group. THC supplementation markedly reduced these parameters and adipocyte hypertrophy and inflammation in white adipose tissues. MVD, TNF-α, VEGF, MMP-2, and MMP-9 were over-expressed in the VHFD group. However, THC supplementation decreased MVD and reduced expression of TNF-α, VEGF, MMP-2, and MMP-9. In conclusion, THC suppressed angiogenesis in adipose tissue by the downregulation of TNF-α, VEGF, MMP-2, and MMP-9. With its effects on lipid metabolism as well as on food consumption, THC could contribute to lower visceral fat and body weight. Overall, our study demonstrated the potential benefit of THC in mitigating obesity and associated metabolic disorders along with elucidated the suppression of adipose angiogenesis as one of its underlying mechanisms.

2.
Adv Physiol Educ ; 47(3): 625-632, 2023 Sep 01.
Article in English | MEDLINE | ID: mdl-37411012

ABSTRACT

The COVID-19 pandemic has disrupted traditional face-to-face human physiology teaching for students at the Faculty of Medicine, Thammasat University, Thailand since February 2020. An online curriculum for both lectures and laboratory sessions was developed to continue the education. This work compared the effectiveness of online physiology labs to the traditional onsite counterparts for 120 dental and pharmacy sophomore students during the 2020 academic year. The method used was a Microsoft Teams synchronous online laboratory experience consisting of eight topics. Faculty lab facilitators created protocols, video scripts, online assignments, and instruction notes. Group lab instructors prepared and delivered the content for recording and led the student discussion. Data recording and live discussion were synchronized and executed. The response rates for the control (2019) and study (2020) groups were 36.89 and 60.83%, respectively. The control group reported higher satisfaction about general laboratory experience, compared to the online study group. The online group rated the laboratory online experience with equal satisfaction to that of an onsite lab experience. The onsite control group reported 55.26% satisfaction with the equipment instrument, while only 32.88% online group voiced their approval of this measure. It was understandable because the excitement in physiology work relies heavily on the experience of the work (P < 0.027). With the same difficulty index for both academic year examination papers, the nonsignificant difference in academic performance of the control and study groups (59.50 ± 13.50 and 62.40 ± 11.43, respectively) showed the effectiveness of our online synchronous physiology lab teaching. In conclusion, the online physiology learning experience was appreciated when a good design was achieved.NEW & NOTEWORTHY The COVID-19 pandemic has forced physiology educators to use online teaching. At the time of this work, there was no research investigating the effectiveness of online and face-to-face physiology lab teaching in undergraduate students. A synchronized online lab teaching of a virtual lab classroom on the Microsoft Teams platform was successfully implemented. Our data showed that online physiology lab teaching could make the students understand physiology concepts and have the same effectiveness as the onsite lab experience.


Subject(s)
COVID-19 , Pandemics , Humans , Thailand , Students , Curriculum
3.
J Nutr Metab ; 2020: 8374287, 2020.
Article in English | MEDLINE | ID: mdl-32685208

ABSTRACT

BACKGROUND: Inflammation and hypertension are primary mechanisms involving in obesity-associated adverse effects of a high-fat diet. The aim of this study was to evaluate the effects of rice bran extract (RBE) on arterial blood pressure, hepatic steatosis, inflammation, and oxidative stress in high-fat diet (HFD)-induced obese mice. METHODS: Male ICR mice were divided into four groups, including a normal-diet control group, a high-fat diet (HFD) (60% kcal from fat) group, an HFD group treated with RBE (220 mg/kg/day), and an HFD group treated with 1100 mg/kg/day for eight weeks. Besides body weight and arterial blood pressure, we determined liver values of total cholesterol, triglyceride, as well as percent body fat, tumor necrosis factor-α (TNF-α), malondialdehyde (MDA), nuclear factor kappa-B (NF-κB), matrix metalloprotease-9 (MMP-9), cyclooxygenase-2 (COX-2), and mRNA endothelial nitric oxide synthase (eNOS). RESULTS: The HFD group had increased body weight, increased systolic and diastolic blood pressure, liver total cholesterol, triglyceride, NF-κB, COX-2 and MMP-9 protein levels, and decreased mRNA eNOS in the aorta. Mice of the HFD group receiving RBE had reduced diastolic blood pressure, as well as significantly decreased liver and serum TNF-α and MDA levels in the liver, and reduced NF-κB levels in both the liver and heart. CONCLUSIONS: These results demonstrate that RBE decreases diastolic blood pressure, the liver lipid droplet accumulation, liver and myocardial NF-κB, myocardial COX-2 and MMP-9 protein levels, and oxidative stress. Moreover, RBE may improve endothelial function and may alleviate adverse health effects associated with obesity including obesity-associated hypertension.

5.
J Clin Neurosci ; 68: 158-161, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31337580

ABSTRACT

The anatomic variation of Circle of Willis (CW) has been shown to have a great impact on its compensatory capacity during acute ischemic stroke. The purpose of the study was to evaluate the effect of variations in CW on collateral circulation in patients with acute ischemic stroke who had major artery occlusion. Patients with acute ischemic stroke within 4.5 h of stroke onset who had at least moderate severity of stroke (NIHSS ≥ 6), caused by major artery occlusion were included. Multiphase computed tomography angiography (CTA) was performed. Variations in CW on each patient were recorded and compared between those with poor collateral and intermediate-good collateral circulation. There were 66 patients. Mean NIHSS was 15. Forty patients had poor collateral circulation and 26 patients had intermediate-good collateral circulation. There were variations in CW: no visualized posterior communicating artery (PCOM) (31/66, 47%), fetal origin of posterior cerebral artery (25/66, 38%), one anterior cerebral artery, segment A1 (A1) hypoplasia or atresia (16/66, 24%), one PCOM (8/66, 12%), and complete CW (3/66, 5%). Fetal origin of posterior cerebral artery (PCA) was associated with poor collateral circulation (48% vs 23%, p-value = 0.046). This pilot study showed that the presence of fetal origin of PCA was associated with poor collateral circulation in patients with acute ischemic stroke caused by major artery occlusion.


Subject(s)
Circle of Willis/abnormalities , Collateral Circulation/physiology , Posterior Cerebral Artery/abnormalities , Stroke/pathology , Adult , Aged , Aged, 80 and over , Brain Ischemia/pathology , Computed Tomography Angiography/methods , Female , Humans , Male , Middle Aged , Pilot Projects
6.
J Stroke Cerebrovasc Dis ; 27(3): 778-782, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29153302

ABSTRACT

BACKGROUND: Extracranial carotid stenosis can be diagnosed by velocity criteria of carotid duplex. Whether they are accurately applied to define severity of internal carotid artery (ICA) stenosis in Asian patients needs to be proved. The purpose of this study was to evaluate the accuracy of 2 carotid duplex velocity criteria in defining significant carotid stenosis. METHODS: Carotid duplex studies and magnetic resonance angiography were reviewed. Criteria 1 was recommended by the Society of Radiologists in Ultrasound; moderate stenosis (50%-69%): peak systolic velocity (PSV) 125-230 cm/s, diastolic velocity (DV) 40-100 cm/s; severe stenosis (>70%): PSV greater than 230 cm/s, DV greater than 100 cm/s. Criteria 2 used PSV greater than 140 cm/s, DV less than 110 cm/s to define moderate stenosis (50%-75%) and PSV greater than 140 cm/s, DV greater than 110 cm/s for severe stenosis (76%-95%). RESULTS: A total of 854 ICA segments were reviewed. There was moderate stenosis in 72 ICAs, severe stenosis in 50 ICAs, and occlusion in 78 ICAs. Criteria 2 had slightly lower sensitivity, whereas higher specificity and accuracy than criteria 1 were observed in detecting moderate stenosis (criteria 1: sensitivity 95%, specificity 83%, accuracy 84%; criteria 2: sensitivity 92%, specificity 92%, and accuracy 92%). However, in detection of severe ICA stenosis, no significant difference in sensitivity, specificity, and accuracy was found (criteria 1: sensitivity 82%, specificity 99.57%, accuracy 98%; criteria 2: sensitivity 86%, specificity 99.68%, and accuracy 99%). CONCLUSIONS: In the subgroup of moderate stenosis, the criteria using ICA PSV greater than 140 cm/s had higher specificity and accuracy than the criteria using ICA PSV 125-230 cm/s. However, there was no significant difference in detection of severe stenosis or occlusion of ICA.


Subject(s)
Asian People , Carotid Artery, Internal/diagnostic imaging , Carotid Stenosis/diagnostic imaging , Ultrasonography, Doppler, Duplex , Blood Flow Velocity , Carotid Artery, Internal/physiopathology , Carotid Stenosis/ethnology , Carotid Stenosis/physiopathology , Humans , Magnetic Resonance Angiography , Predictive Value of Tests , Regional Blood Flow , Reproducibility of Results , Severity of Illness Index , Thailand/epidemiology
7.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-733669

ABSTRACT

To evaluate the insulin sensitivity action of ferulic acid (FA) in skeletal muscle and hypothalamus of high-fat diet (HFD)-induced obese mice.Methods: Obese mouse model was induced by HFD (45 kcal% lard fat) for 16 weeks. After 8 weeks of HFD feeding, these obese mice were orally treated with FA at doses of 25 and 50 mg/kg/day for 8 weeks. At the end of all treatments, the epididymal fat, pancreas, skeletal muscle and hypothalamus were removed for biochemical parameter and protein expression examinations.Results: FA treatment significantly decreased leptin level in fat tissue and insulin level in pancreas (P < 0.05). Interestingly, obese mice treated with FA increased the protein expressions of insulin receptor substrate-1, phosphatidylinositol 3-kinase, and phosphorylated-protein kinase B in both muscle and brain (P < 0.05). The phosphorylations of adenosine monophosphate-activated protein kinase and acetyl-CoA carboxylase in muscle, and leptin receptor protein in hypothalamus were also increased (P < 0.05). The pancreatic islets histology showed smaller size in obese mice treated with FA compared to untreated obese mice.Conclusions: These findings indicate the beneficial effect of FA in improving insulin resistance in HFD-induced obese mice. These effects are probably mediatedvia modulating the insulin receptor substrate/phosphatidylinositol 3-kinase/protein kinase B or adenosine monophosphate-activated protein kinase pathways.

8.
J Clin Neurosci ; 46: 37-40, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28890029

ABSTRACT

More than half of patients with dementia lived in countries with low and middle incomes. However, there have been few studies on the natural course of disease in these countries. The purpose of this study was to study the natural course and the predictive factors of advanced stage and death in Thai patients with dementia. Patients with dementia who were treated in neurologic and psychiatric clinic from September 2004 to February 2016, were included. Data about natural course of diseases, behavioral and psychological symptoms in dementia (BPSD) and complications were studied. 207 patients were included. Mean age was 77years old. Mean Thai Mental State Examination (TMSE) was 17.5. Alzheimer's disease was the most common cause of dementia (55%). With the mean follow-up of 39months (range from 2 to 126months), 64% of the patients had BPSD. Sixty-two patients (30%) had complications required admission. Seven patients died. Fifty-four patients (29%) ended in the advanced stage of dementia. Mean duration from diagnosis to the advanced stage was 49months. Complications that required admission usually occurred in moderate to severe dementia and were strongly associated with the advanced stage or death (OR 6.1, 95%CI 2.57-14.49, p-value<0.0001). Alzheimer's disease was the most common cause of dementia in the study. Most demented patients presented in moderate severity of dementia. Mean duration from diagnosis to the advanced stage of dementia was approximate 4-5years. Complications required admissions related to the progression to advanced stage or death.


Subject(s)
Dementia , Aged , Aged, 80 and over , Dementia/complications , Dementia/mortality , Disease Progression , Female , Humans , Male , Middle Aged , Thailand
9.
Clin Exp Pharmacol Physiol ; 43(12): 1234-1242, 2016 12.
Article in English | MEDLINE | ID: mdl-27562725

ABSTRACT

Reduced vesicular glutamate transporter 1 (VGLUT1) and 2 (VGLUT2) indicate glutamatergic hypofunction leading to cognitive impairment in schizophrenia. However, VGLUT3 involvement in cognitive dysfunction has not been reported in schizophrenia. Brahmi (Bacopa monnieri) might be a new treatment and prevention for cognitive deficits in schizophrenia by acting on cerebral VGLUT3 density. We aimed to study cognitive enhancement- and neuroprotective-effects of Brahmi on novel object recognition and cerebral VGLUT3 immunodensity in sub-chronic (2 mg/kg, Bid, ip) phencyclidine (PCP) rat model of schizophrenia. Rats were assigned to three groups for cognitive enhancement effect study: Group 1, Control; Group 2, PCP administration; Group 3, PCP+Brahmi. A neuroprotective-effect study was also carried out. Rats were again assigned to three groups: Group 1, Control; Group 2, PCP administration; Group 3, Brahmi+PCP. Discrimination ratio (DR) representing cognitive ability was obtained from a novel object recognition task. VGLUT3 immunodensity was measured in the prefrontal cortex, striatum and cornu ammonis fields 1-3 (CA1-3) using immunohistochemistry. We found reduced DR in the PCP group, which occurred alongside VGLUT3 reduction in all brain areas. PCP+Brahmi showed higher DR score with increased VGLUT3 immunodensity in the prefrontal cortex and striatum. Brahmi+PCP group showed a higher DR score with increased VGLUT3 immunodensity in the prefrontal cortex, striatum and CA1-3. We concluded that reduced cerebral VGLUT3 was involved in cognitive deficit in PCP-administrated rats. Receiving Brahmi after PCP restored cognitive deficit by increasing VGLUT3 in the prefrontal cortex and striatum. Receiving Brahmi before PCP prevented cognitive impairment by elevating VGLUT3 in prefrontal cortex, striatum and CA1-3. Therefore, Brahmi could be a new frontier of restoration and prevention of cognitive deficit in schizophrenia.


Subject(s)
Bacopa , Phencyclidine/toxicity , Plant Extracts/therapeutic use , Recognition, Psychology/physiology , Schizophrenia/metabolism , Vesicular Glutamate Transport Proteins/biosynthesis , Animals , Brain/drug effects , Brain/metabolism , Disease Models, Animal , Male , Phencyclidine/administration & dosage , Plant Extracts/isolation & purification , Plant Extracts/pharmacology , Rats , Rats, Wistar , Recognition, Psychology/drug effects , Schizophrenia/chemically induced , Schizophrenia/drug therapy
10.
Clin Exp Pharmacol Physiol ; 43(2): 242-50, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26541794

ABSTRACT

Ferulic acid (FA) is a plant phenolic acid that has several pharmacological effects including antihyperglycaemic activity. Thus, the objective of this study is to investigate the effect of FA on glucose and lipid metabolism in high-fat diet (HFD)-induced obese mice. Institute for Cancer Research (ICR) mice were fed a HFD (45 kcal% fat) for 16 weeks. At the ninth week of induction, the obese mice were orally administered with daily FA doses of 25 and 50 mg/kg for the next eight weeks. The results show that FA significantly reduced the elevated blood glucose and serum leptin levels, lowered the insulin resistance, and increased the serum adiponectin level. Moreover, serum lipid level, and liver cholesterol and triglyceride accumulations were also reduced. The histological examination showed clear evidence of a decrease in the lipid droplets in liver tissues and smaller size of fat cells in the adipose tissue in the obese mice treated with FA. Interestingly, FA reduced the expression of hepatic lipogenic genes such as sterol regulatory element-binding protein 1c (SREBP1c), fatty acid synthase (FAS), and acetyl-CoA carboxylase (ACC). It could also up-regulate hepatic carnitine palmitoyltransferase 1a (CPT1a) gene and peroxisome proliferator-activated receptor alpha (PPARα) proteins. The FA treatment was also found to suppress the protein expressions of hepatic gluconeogenic enzymes, phosphoenolpyruvate carboxylase (PEPCK) and glucose-6-phosphatase (G6Pase). In conclusion, the findings of this study demonstrate that FA improves the glucose and lipid homeostasis in HFD-induced obese mice probably via modulating the expression of lipogenic and gluconeogenic genes in liver tissues.


Subject(s)
Coumaric Acids/pharmacology , Diet, High-Fat/adverse effects , Glucose/metabolism , Homeostasis/drug effects , Lipid Metabolism/drug effects , Obesity/metabolism , Animals , Coumaric Acids/therapeutic use , Gene Expression Regulation/drug effects , Insulin Resistance , Lipogenesis/drug effects , Liver/drug effects , Liver/metabolism , Male , Mice , Mice, Obese , Obesity/drug therapy , Obesity/genetics
11.
J Med Assoc Thai ; 99 Suppl 4: S222-9, 2016 Jul.
Article in English | MEDLINE | ID: mdl-29926716

ABSTRACT

Background: Decreased vesicular glutamate transporter type 1 (VGLUT1) has been reported in the brains of both postmortem and animal models of schizophrenia. It indicates the deficit of glutamatergic function which is implicated in the cognitive deficit in schizophrenia. Our previous study investigated that Brahmi can recover the cognitive deficit in schizophrenia by upregulating cerebral VGLUT1 density. However, the neuroprotective effects of Brahmi have not been studied yet. Objective: To study the effects of Brahmi on the prevention of cognitive deficit and cerebral VGLUT1 density in sub-chronic phencyclidine (PCP) rat model of schizophrenia. Material and Method: Rats were assigned to three groups; Group-A: Control, Group-B: PCP administration and Group- C: Brahmi + PCP. Cognitive ability was represented by the Discrimination ratio (DR) calculated from novel object recognition test. VGLUT1 optical density was measured in prefrontal cortex, striatum, cornu ammonis fields 1 (CA1) and 2/3 (CA2/3) and dentate gyrus (DG) of the hippocampus using immunohistochemistry. Results: DR in PCP group was significantly decreased compared with control. This occurred alongside significantly reduced VGLUT1 in prefrontal cortex and CA2/3. Brahmi + PCP group showed a significant increase in DR score compared with PCP alone; however, it was still lower than control. This occurred alongside significant increase in VGLUT1 in CA2/3. Conclusion: Cognitive deficit observed in PCP-administered rats was mediated by VGLUT1 reduction in prefrontal cortex and CA2/3. Interestingly, Brahmi could prevent this cognitive deficit by maintaining VGLUT1 density in CA2/3 in normal level.


Subject(s)
Bacopa , Hippocampus/metabolism , Neuroprotective Agents/pharmacology , Nootropic Agents/pharmacology , Prefrontal Cortex/metabolism , Schizophrenia/drug therapy , Animals , Behavior, Animal , Brain/drug effects , Brain/metabolism , Cognition/drug effects , Cognition Disorders/drug therapy , Disease Models, Animal , Male , Neostriatum/metabolism , Phencyclidine , Rats , Rats, Wistar , Schizophrenia/pathology , Vesicular Glutamate Transport Protein 1/metabolism
12.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-500664

ABSTRACT

Objective: To investigate the effect of Rhinacanthus nasutus (R. nasutus) leaf extract on impaired glucose and lipid metabolism in obese ICR mice. Methods: Obesity was induced in the male ICR mice by feeding them a high-fat diet (60 kcal% fat) for 12 weeks. After the first six weeks of the diet, the obese mice were administered with the water extract of R. nasutus leaves at 250 and 500 mg/kg per day for the next six weeks. Subsequently, the blood glucose, lipid profiles, insulin, leptin, and adiponectin levels were measured. The liver and adipose tissues were excised for his-topathological examination and protein expression study. Results: After six weeks of the treatment, R. nasutus extract (at 250 and 500 mg/kg per day) was found to reduce the elevated blood glucose level, improve the insulin sensitivity, decrease the serum leptin, and increase the serum adiponectin levels. The obese mice treated with R. nasutus were found to have a reduction in the increased lipid concen-trations in their serum and liver tissues. Moreover, treatment with R. nasutus reduced the fat accumulation in the liver and the large adipocyte size in the fat tissues. Interestingly, the administration with R. nasutus extract was marked by an increase in the hepatic peroxisome proliferators-activated receptor alpha, fat cell adiponectin, and glucose transporter 4 proteins. Conclusions: To the best of our knowledge, the present study is the first report on the impact of R. nasutus extract in improving the impaired glucose and lipid metabolism in high-fat diet-induced obesity in mice via stimulating the insulin sensitivity in the liver and adipose tissues.

13.
J Med Assoc Thai ; 98 Suppl 3: S7-15, 2015 Apr.
Article in English | MEDLINE | ID: mdl-26387382

ABSTRACT

BACKGROUND: Glutamatergic hypofunction is affected in schizophrenia. The decrement ofpresynaptic glutamatergic marker remarkably vesicular glutamate transporter type 1 (VGLUT1) indicates the deficit ofglutamatergic and cognitive function in schizophrenic brain. However there have been afew studies in VGLUT2. Brahmi, a traditional herbal medicine, might be a new frontier of cognitive deficit treatment and prevention in schizophrenia by changing cerebral VGLUT2 density. OBJECTIVE: To study cognitive enhancement- and neuroprotective-effects of Brahmi on novel object recognition task and cerebral VGLUT2 immunodensity in sub-chronic phencyclidine (PCP) rat model of schizophrenia. MATERIAL AND METHOD: Cognitive enhancement effect study; rats were assigned to three groups; Group-1: Control, Group-2: PCP administration and Group-3: PCP + Brahmi. Neuroprotective effect study; rats were assigned to three groups; Group-1: Control, Group-2: PCP administration and Group-3: Brahmi + PCP Discrimination ratio (DR) representing cognitive ability was obtained from novel object recognition task. VGLUT2 immunodensity was measured in prefrontal cortex, striatum, cornu ammonis fields 1 (CA1) and 2/3 (CA2/3) of hippocampus using immunohistochemistry. RESULTS: DR was significantly reduced in PCP group compared with control. This occurred alongside VGLUT2 reduction in prefrontal cortex, but not in striatum, CA1 or CA2/3. Both PCP + Brahmi and Brahmi + PCP groups showed an increased DR score up to normal, which occurred alongside a significantly increased VGLUT2 immunodensity in the prefrontal cortex, compared with PCP group. CONCLUSION: The decrement of VGLUT2 density in prefrontal cortex resulted in cognitive deficit in rats receiving PCP. Interestingly, receiving Brahmi after PCP administration can restore this cognitive deficit by increasing VGLUT2 density in prefrontal cortex. This investigation is defined as Brahmi's cognitive enhancement effect. Additionally, receiving Brahmi before PCP administration can also prevent cognitive impairment by elevating VGLUT2 density in prefrontal cortex. This observation indicates neuroprotective effect of Brahmi. Therefore, Brahmi could be a new frontier of restoration and prevention of cognitive deficit in schizophrenia.


Subject(s)
Bacopa , Cognition Disorders/prevention & control , Nootropic Agents/pharmacology , Prefrontal Cortex/metabolism , Schizophrenia/metabolism , Vesicular Glutamate Transport Protein 1/metabolism , Animals , Brain/drug effects , Cognition/drug effects , Disease Models, Animal , Hippocampus/metabolism , Male , Phencyclidine , Phytotherapy , Prefrontal Cortex/drug effects , Rats , Rats, Wistar , Schizophrenia/physiopathology , Vesicular Glutamate Transport Protein 1/drug effects
14.
J Med Assoc Thai ; 98 Suppl 2: S56-63, 2015 Mar.
Article in English | MEDLINE | ID: mdl-26211105

ABSTRACT

BACKGROUND: Cognitive deficit is a significant problem, which finally occurs in all schizophrenic patients. It can not be attenuated by any antipsychotic drugs. It is well known that changes of neuronal density are correlated with learning and memory deficits. Bacopa monnieri (Brahmi), popularly known as a cognitive enhancer; might be a novel therapeutic agentfor cognitive deficit in schizophrenia by changing cerebral neuronal density. The objective of this study was to determine the effects of Brahmi on attenuation at cognitive deficit and on the neuronal density in the prefrontal cortex, striatum and cornu ammonis subfield 1 (CA1) and 2/3 (CA2/3) of hippocampus in sub-chronic phencyclidine (PCP) rat model of schizophrenia. MATERIAL AND METHOD: Rats were assigned to three groups; Group-1: Control, Group-2: PCP administration and Group-3: PCP + Brahmi. Rats were testedfor cognitive ability by using the novel object recognition test. Neuronal density from a serial Nissl stain sections ofthe prefrontal cortex, striatum and hippocampus ofrat model ofschizophrenia were measured by using Image ProPlus software and manual counting. RESULTS: Sub-chronic administration of PCP results in cognitive deficits in novel object recognition task. This occurred alongside significantly increased neuronal density in CA1. The cognitive deficit was recovery to normal in PCP + Brahmi group and it occurred alongside significantly decreased neuronal density in CA1. On the other hand, significantly increased neuronal density was observed in CA2/3 of PCP + Brahmi group compared with PCP alone. CONCLUSION: Brahmi is a potential cognitive enhancer against schizophrenia. It reduces neuronal density, most likely glutamatergic neuron, which results in neuronal toxicity and cognitive deficit. Therefore, Brahmi has cognitive enhancement effect by reducing glutamatergic neuron in CAI. Moreover, it also has neurogenesis effect in CA2/3, which is needed to be investigated in the further study.


Subject(s)
Bacopa/chemistry , Nootropic Agents/pharmacology , Plant Extracts/pharmacology , Recognition, Psychology/drug effects , Schizophrenia/drug therapy , Animals , Brain/cytology , Brain/drug effects , Brain/physiology , Disease Models, Animal , Male , Neurons/drug effects , Rats , Rats, Wistar
15.
J Med Assoc Thai ; 97 Suppl 8: S50-5, 2014 Aug.
Article in English | MEDLINE | ID: mdl-25518293

ABSTRACT

BACKGROUND: Cognitive impairment is a major problem, which eventually develops in schizophrenia. It contributes to the patients 'functional disability and cannot be attenuated by antipsychotic drugs. Bacopa monnieri (Brahmi), a neuroprotective herbal medicine in the elderly, might be a novel neuroprotective agent for prevention of cognitive deficit in schizophrenia. OBJECTIVE: To study neuroprotective effects ofBrahmi on novel object recognition task and cerebral glutamate/N-methyl-D- aspartate receptor subtype 1 (NMDAR1) immunodensity in sub-chronic phencyclidine (PCP) rat model ofschizophrenia. MATERIAL AND METHOD: Rats were assigned to three groups; Group-A: Control, Group-B: PCP administration and Group- C: Brahmi + PCP. Discrimination ratio (DR) representing cognitive ability was obtainedfrom novel object recognition task. NMDAR1 immunodensity was measured in prefrontal cortex, striatum, cornu ammonis fields I (CA 1) and 2/3 (CA2/3) and dentate gyrus (DG) using immunohistochemistry. RESULTS: DR was significantly reduced in PCP group compared with control. This occurred alongside NMDAR1 up-regulation in CA2/3 and DG but not in prefrontal cortex, striatum or CA1. Brahmi + PCP group showed an increased DR score up to normal which occurred alongside a significantly decreased NMDARI immunodensity in CA2/3 and DG compared with PCP group. CONCLUSION: Cognitive deficit observed in rats receiving PCP was mediated by NMDAR1 up-regulation in CA2/3 and DG Interestingly, receiving Brahmi before PCP administration can restore this cognitive deficit by decreasingNMDAR1 in these brain areas. Therefore, Brahmi could be a novel neuroprotective agentfor the prevention ofcognitive deficit in schizophrenia.


Subject(s)
Bacopa , Behavior, Animal/drug effects , Brain/drug effects , Neuroprotective Agents/pharmacology , Phytotherapy , Plant Extracts/pharmacology , Receptors, N-Methyl-D-Aspartate/drug effects , Schizophrenia/chemically induced , Animals , Brain/metabolism , Cognition/drug effects , Hippocampus/drug effects , Hippocampus/metabolism , Immunohistochemistry , Male , Neostriatum/drug effects , Neostriatum/metabolism , Phencyclidine/toxicity , Prefrontal Cortex/drug effects , Prefrontal Cortex/metabolism , Rats , Rats, Wistar , Receptors, N-Methyl-D-Aspartate/metabolism
16.
J Med Assoc Thai ; 96(2): 231-8, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23936991

ABSTRACT

BACKGROUND: Cognitive impairment is a common characteristic in schizophrenia that cannot be attenuated by antipsychotics. Brahmi, popularly known as a cognitive enhancer might be a new frontier of cognitive deficit treatment in schizophrenia. OBJECTIVE: To study effects of Brahmi on attenuation at cognitive deficit and cerebral glutamate/N-methyl-D-aspartate (NMDA) receptor density in sub-chronic phencyclidine (PCP) rat model of schizophrenia. MATERIAL AND METHOD: Rats were administered PCP or vehicle. Half of the PCP-group was treated with Brahmi. Discrimination ratio (DR) representing cognitive ability was obtained from novel object recognition task. NMDA immunodensity was measured in prefrontal cortex, striatum, cornu ammonis fields 1 to 3 of hippocampus (CA1-3), and dentate gyrus (DG) using immunohistochemistry. RESULTS: DR in PCP-group was significantly decreased compared with control. This occurred alongside NMDA up-regulation in prefrontal cortex and CA1-3, but not in striatum and DG. PCP with Brahmi showed a significant increase in DR score compared with PCP alone. This occurred alongside significant decrease in NMDA immunodensity in prefrontal cortex and CA1-3. No significant difference in cerebral NMDA immunodensity was observed between PCP with Brahmi and control. CONCLUSION: Cognitive deficit observed in PCP-administered rats was mediated by NMDA up-regulation in prefrontal cortex and CA1-3. Interestingly, Brahmi could recover this cognitive deficit by decreasing NMDA density in these brain areas to normal.


Subject(s)
Bacopa , Cognition Disorders/drug therapy , Cognition , Nootropic Agents/pharmacology , Phytotherapy , Animals , Disease Models, Animal , Hallucinogens/adverse effects , Hippocampus/metabolism , Image Processing, Computer-Assisted , Immunohistochemistry , Male , Phencyclidine/adverse effects , Prefrontal Cortex/metabolism , Rats , Rats, Wistar , Receptors, N-Methyl-D-Aspartate , Schizophrenia/chemically induced
17.
J Med Assoc Thai ; 96(5): 625-32, 2013 May.
Article in English | MEDLINE | ID: mdl-23745319

ABSTRACT

BACKGROUND: Decreased vesicular glutamate transporter type 1 (VGLUT1) in schizophrenic brain indicates the deficit of glutamatergic function, which may produce cognitive impairment in the patients. Brahmi might be a novel therapeutic agent for the cognitive deficit treatment in schizophrenia by changing cerebral VGLUT1 density. OBJECTIVE: To study effects of Brahmi on attenuation at cognitive deficit and cerebral VGLUT1 density in sub-chronic phencyclidine (PCP) rat model of schizophrenia. MATERIAL AND METHOD: Rats were administered PCP or vehicle. Half of the PCP-group was treated with Brahmi. Discrimination ratio (DR) representing cognitive ability was obtained from novel object recognition test. VGLUT1 density was measured in prefrontal cortex, striatum, cornu ammonis fields 1 (CA1) and 2/3 (CA2/3) of hippocampus and dentate gyrus (DG) using western blot and immunohistochemistry. RESULTS: DR in PCP-group was significantly decreased compared with control. This occurred alongside reduced VGLUT1 in prefrontal cortex, striatum, CA1 and CA2/3. PCP with Brahmi showed a significant increase in DR score compared with PCP alone. This occurred alongside significant increase in VGLUT1 in CA1 and CA2/3. CONCLUSION: Cognitive deficit observed in PCP-administered rats was mediated by VGLUT1 reduction in prefrontal cortex, striatum, CA1 and CA2/3. Interestingly, Brahmi could recover this cognitive deficit by increasing VGLUT1 in CA1 and CA2/3 to normal.


Subject(s)
Bacopa , Behavior, Animal/drug effects , Brain , Cognition Disorders , Phytotherapy , Schizophrenia , Vesicular Glutamate Transport Protein 1/metabolism , Animals , Brain/drug effects , Brain/metabolism , Brain/physiopathology , Cognition Disorders/drug therapy , Cognition Disorders/etiology , Cognition Disorders/metabolism , Cognition Disorders/physiopathology , Disease Models, Animal , Drug Monitoring , Male , Nootropic Agents/administration & dosage , Plant Preparations , Rats , Rats, Wistar , Schizophrenia/complications , Schizophrenia/metabolism , Schizophrenia/pathology , Schizophrenia/physiopathology , Treatment Outcome
18.
ISRN Pharmacol ; 2012: 480265, 2012.
Article in English | MEDLINE | ID: mdl-22530143

ABSTRACT

Piper interruptum Opiz. and Piper chaba Linn. are herbaceous plants in the Piperaceae family. The ethanol extract of P. interruptum and P. chaba inhibited ethyl phenylpropiolate-induced ear edema and carrageenan-induced hind paw edema in rats. Both extracts reduced transudative and granuloma weights as well as body weight gain and thymus weight of the chronic inflammatory model using cotton pellet-induced granuloma formation in rats. Moreover, both extracts exhibited analgesic activity on both early phase and late phase of formalin test in mice and also showed antipyretic activity on yeast-induced hyperthermia in rats.

19.
Article in English | MEDLINE | ID: mdl-23983382

ABSTRACT

Toxicity tests of 95% ethanol extract of the root of Antidesma acidum were studied in male and female rats. The oral acute toxicity test at 5,000 mg/kg revealed that the ethanol extract did not produce toxic effects on signs, general behavious, mortality and gross appearance of internal organs of rats. Furthermore, the oral sub-acute toxicity test at the dose of 1,000 mg/kg/day displayed no significant changes in body and internal organs' weights, normal hematological and clinical blood chemistry values. Histological examination also showed normal architecture of all internal organs. In conclusion, the ethanol extract of Antidesma acidum did not produce any toxicity in oral acute and suba-cute toxicity studies.


Subject(s)
Euphorbiaceae , Plant Extracts/pharmacology , Animals , Euphorbiaceae/adverse effects , Female , Male , Plant Extracts/adverse effects , Plant Roots , Rats , Rats, Sprague-Dawley , Toxicity Tests, Acute
20.
Article in English | MEDLINE | ID: mdl-23983384

ABSTRACT

Chantaleela recipe is indicated for relieving fever in Thai traditional folk medicine. In the present study, Chantaleela recipe was investigated for anti-inflammatory, analgesic, antipyretic and anti-ulcerogenic activities. In preliminary investigation Chantaleela recipe was found to exert an inhibitory activity on the acute phase of inflammation as seen in ethyl phenylpropiolate-induced ear edema as well as in carrageenan-induced hind paw edema in rats. The results suggest that the anti-inflammatory activity of Chantaleela recipe may be due to an inhibition via cyclooxygenase pathway. In the analgesic test, Chantaleela recipe showed a significant analgesic activity in both the early and late phases of formalin test, but exerted the most pronounced effect in the late phase. The analgesic activity of Chantaleela recipe may act via mechanism at peripheral and partly central nervous system. In antipyretic test, Chantaleela recipe significantly decreased rectal temperature of brewer's yeast-induced hyperthermia rats, probably by inhibiting synthesis and/or release of prostaglandin E2 in the hypothalamus. Therefore, the key mechanism of anti-inflammatory, analgesic, and antipyretic activity of the Chantaleela recipe likely involves the inhibition of the synthesis and/or release of inflammatory or pain mediators, especially prostaglandins. The oral administration of the Chantaleela recipe reduced ulcer formation in acute gastric ulcer models (EtOH/HCl-, indomethacin-, and stress-induced gastric lesions). In contrast, this recipe did not reduce the secretory rate, total acidity, and increase pH in rat stomach. These results indicated that Chantaleela seem to possess anti-ulcerogenic effect. This activity may be due to the increase of gastric mucosal resistance or potentiation of defensive factors and/or the decrease of aggressive factors but did not associate the anti-secretory activity. Moreover, the high oral doses treated did not cause acute toxicity in rats and the long term oral administration did not produce gastric and ileum lesions.


Subject(s)
Analgesics/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Anti-Ulcer Agents/therapeutic use , Antipyretics/therapeutic use , Magnoliopsida , Medicine, Traditional , Plant Preparations/therapeutic use , Analgesics/pharmacology , Animals , Anti-Inflammatory Agents/pharmacology , Anti-Ulcer Agents/pharmacology , Antipyretics/pharmacology , Carrageenan , Dinoprostone/metabolism , Edema/chemically induced , Edema/prevention & control , Fever/microbiology , Fever/prevention & control , Formaldehyde , Gastric Mucosa/drug effects , Indomethacin , Inflammation/drug therapy , Inflammation/metabolism , Inflammation Mediators/metabolism , Male , Mice , Pain/chemically induced , Pain/drug therapy , Phytotherapy , Plant Preparations/pharmacology , Prostaglandin-Endoperoxide Synthases/metabolism , Rats, Sprague-Dawley , Stomach Ulcer/chemically induced , Stomach Ulcer/etiology , Stomach Ulcer/prevention & control , Thailand
SELECTION OF CITATIONS
SEARCH DETAIL
...